BridgeBio Pharma (BBIO) Non Operating Income (2018 - 2026)

BridgeBio Pharma has reported Non Operating Income for 9 years, with the latest figure at -$60.6 million in Q1 2026.

• Quarterly Non Operating Income rose 7.11% year-over-year to -$60.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$204.5 million (down 1027.4% YoY) and the FY2025 annual result came in at -$209.1 million, down 511.77% from the prior year.
• Non Operating Income slipped to -$60.6 million in Q1 2026 per BBIO's latest filing, from -$55.2 million in the prior quarter.
• Over five years, Non Operating Income peaked at $100.0 million in Q2 2024 and troughed at -$65.2 million in Q1 2025.
• A 5-year average of -$14.0 million and a median of -$21.8 million in 2023 frame the typical range for Non Operating Income.
• The widest YoY moves for Non Operating Income: up 1063.11% in 2022, down 672.83% in 2022.
• Over 5 years, Non Operating Income stood at -$11.3 million in 2022, then soared by 162.52% to $7.1 million in 2023, then slumped by 667.28% to -$40.2 million in 2024, then slumped by 37.27% to -$55.2 million in 2025, then retreated by 9.79% to -$60.6 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered -$60.6 million, -$55.2 million, and -$41.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.